PT - JOURNAL ARTICLE AU - Cummings, Steven R. AU - Chetham, Scott AU - Lee, Andy TI - A Method to Redesign and Simplify Schedules of Assessment and Quantify the Impacts. Applications to Merck Protocols AID - 10.1101/2024.01.02.24300749 DP - 2024 Jan 01 TA - medRxiv PG - 2024.01.02.24300749 4099 - http://medrxiv.org/content/early/2024/01/08/2024.01.02.24300749.short 4100 - http://medrxiv.org/content/early/2024/01/08/2024.01.02.24300749.full AB - The growing complexity of biopharmaceutical sponsored trials has adverse impacts on increased burdens on participants, clinical sites, and sponsors, including greater difficulty recruiting and retaining participants, difficulty engaging sites to participate in trials, excessive cost of trials, and increased cycle times. The schedule of assessments (SoAs) is the origin of and blueprint for complexity that is often generated by copying and pasting from previous SoAs. We developed an approach, termed Lean Design, for redesigning SoAs, restarting SoAs from ‘ground zero’, challenging the addition of assessments using several principles of trial design. We employed a system, the Faro Trial Designer Tool, to quantify the impacts of changes in an SoA to provide real-time feedback to the team and sponsor. We applied the approach in workshops with teams for six clinical trials in various stages of design and implementation. The approach resulted in recommendation for substantial savings in participant and site staff time, costs, and complexity of the trials. Application of this approach to very early stages of protocol design has the potential to reduce the complexity of biopharmaceutical sponsored trials and its consequences.Competing Interest StatementDr. Cummings received consultation fees from Merck and Faro Health Dr. Chetham is the CEO of Faro Health Mr. Lee is Head of Global Clinical Trial Operations, Merck & Co., Rahway, NJ, USAFunding StatementSupport for efforts involved in the projects was part of the employment with Merck & Co., Inc. or Faro Health There was no other funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe analyses of the hours and cost savings use a proprietary database and software system. No data had been collected by the protocols analyzed in the report.